SMBT
BMRN icon

Southern Michigan Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Southern Michigan Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72K Hold
100
– – ﹤0.01% 358
2026
Q1 		$5.65K Buy
+100
New +$5.83K ﹤0.01% 351

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Southern Michigan Bank & Trust's BMRN Position: Q2 2026 in Review

Southern Michigan Bank & Trust held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 100 shares worth $5.72K. The position accounts for ﹤0.01% of the portfolio, ranked #358.

Southern Michigan Bank & Trust first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Southern Michigan Bank & Trust held 100 shares of BioMarin Pharmaceuticals worth $5.72K as of Q2 2026.
  • Southern Michigan Bank & Trust left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Southern Michigan Bank & Trust's portfolio in Q2 2026, its #358 holding.
  • Southern Michigan Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Southern Michigan Bank & Trust's 13F filing for Q2 2026, filed 21 Jul 2026.